Diadema Partners’s Relmada Therapeutics RLMD Stock Holding History

Diadema Partners’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5M	Buy	361,367 +160,525	+80%	+$1.12M	0.32%	71
2026 Q1	$1.4M	Sell	200,842 -188,553	-48%	-$892K	0.24%	76
2025 Q4	$1.88M	Buy	+389,395	New	+$1.3M	0.32%	68

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diadema Partners's RLMD Position: Q2 2026 in Review

Diadema Partners increased its Relmada Therapeutics (RLMD) stake by 80% in Q2 2026, buying an estimated $1.12M and bringing the position to 361,367 shares worth $2.5M. The position accounts for 0.32% of the portfolio, ranked #71.

Diadema Partners first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Diadema Partners held 361,367 shares of Relmada Therapeutics worth $2.5M as of Q2 2026.
Diadema Partners bought 160,525 Relmada Therapeutics shares in Q2 2026, an estimated $1.12M.
Relmada Therapeutics made up 0.32% of Diadema Partners's portfolio in Q2 2026, its #71 holding.
Diadema Partners first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.